Collegium Pharmaceutical, Inc. (NASDAQ:COLL) insider Alison B. Fleming sold 4,601 shares of the stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $17.25, for a total transaction of $79,367.25. Following the transaction, the insider now owns 28,513 shares in the company, valued at $491,849.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of Collegium Pharmaceutical, Inc. (COLL) traded down $2.28 on Thursday, reaching $16.30. 2,848,700 shares of the company’s stock traded hands, compared to its average volume of 490,803. Collegium Pharmaceutical, Inc. has a 52 week low of $7.37 and a 52 week high of $19.21.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.28. The company had revenue of $11.95 million during the quarter, compared to the consensus estimate of $5.31 million. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. Collegium Pharmaceutical’s revenue was up 2814.6% compared to the same quarter last year. During the same period last year, the firm earned ($1.13) earnings per share. equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post -2.56 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.watchlistnews.com/alison-b-fleming-sells-4601-shares-of-collegium-pharmaceutical-inc-coll-stock/1722309.html.

COLL has been the subject of several recent analyst reports. HC Wainwright initiated coverage on shares of Collegium Pharmaceutical in a research note on Monday, September 11th. They issued a “buy” rating and a $21.00 target price for the company. BidaskClub downgraded shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Jefferies Group LLC restated a “buy” rating and issued a $15.00 target price on shares of Collegium Pharmaceutical in a research note on Thursday, September 21st. Needham & Company LLC restated a “buy” rating and issued a $25.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $14.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, September 8th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $19.33.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Pura Vida Investments LLC purchased a new position in shares of Collegium Pharmaceutical in the third quarter worth $1,229,000. Wells Fargo & Company MN raised its holdings in shares of Collegium Pharmaceutical by 12.8% in the third quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock worth $475,000 after buying an additional 5,136 shares during the last quarter. Citadel Advisors LLC raised its holdings in shares of Collegium Pharmaceutical by 773.8% in the third quarter. Citadel Advisors LLC now owns 544,033 shares of the specialty pharmaceutical company’s stock worth $5,707,000 after buying an additional 481,771 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in shares of Collegium Pharmaceutical in the third quarter worth $192,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Collegium Pharmaceutical in the third quarter worth $201,000. 77.23% of the stock is owned by institutional investors and hedge funds.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.